Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms CARMEN CD 306
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 18 Dec 2021 This trial has been completed in Portugal(End date-2020-08-18), according to European Clinical Trials Database.
- 30 Dec 2020 This trial has been completed in Greece (End date-2020-08-18), according to European Clinical Trials Database.
- 05 Dec 2020 This trial has been completed in Slovakia, according to European Clinical Trials Database.